Literature DB >> 31188744

Only serum pepsinogen I and pepsinogen I/II ratio are specific and sensitive biomarkers for screening of gastric cancer.

Fariborz Mansour-Ghanaei1, Farahnaz Joukar1, Massood Baghaee2, Masood Sepehrimanesh2, Amineh Hojati3.   

Abstract

Purpose We aimed to determine optimal cut-off points of plasma levels of ghrelin and serum levels of pepsinogen I, II, and their ratio for screening of gastric cancer (GC). Methods Blood samples were taken from 41 patients with confirmed gastric cancer along with 82 patients without malignancy. Serum levels of pepsinogen I and II, plus plasma levels of acylated ghrelin were measured using commercial ELISA kits. Results The case group had significant lower plasma levels of ghrelin, pepsinogen I, and pepsinogen I/II ratio in comparison to the control group (P<0.001). In the control group, there was significant higher serum pepsinogen I (P=0.028) and pepsinogen II (P=0.003) and lower pepsinogen I/II ratio (P=0.020) in males versus females; significantly higher serum pepsinogen II (P=0.047) and lower pepsinogen I/II ratio (P=0.030) in overweight compared to normal weight patients; and significantly lower pepsinogen I/II ratio (P=0.030) in smokers versus non-smoker. In the case group, there was only significantly lower pepsinogen I (P=0.006) in males versus females, and significantly lower plasma ghrelin (P=0.017) in overweight compared to normal weight patients. The characteristic curve analysis indicated that pepsinogen I at a cut-off of 70.95 μg/L and pepsinogen I/II ratio at cut-off of 2.99, had good sensitivity and specificity. Conclusions Just serums levels of pepsinogen I and the ratio of pepsinogen I/II can be used as biomarker to screen GC.

Entities:  

Keywords:  Ghrelin; biomarker; gastric cancer (GC); pepsinogen

Mesh:

Substances:

Year:  2019        PMID: 31188744     DOI: 10.1515/bmc-2019-0010

Source DB:  PubMed          Journal:  Biomol Concepts        ISSN: 1868-5021


  5 in total

1.  Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an asian population.

Authors:  Cong Long Nguyen; Tran Tien Dao; Thi-Thuy Ngan Phi; The Phuong Nguyen; Van Tuyen Pham; Truong Khanh Vu
Journal:  Ann Med Surg (Lond)       Date:  2022-05-27

Review 2.  Molecular Alterations in Gastric Intestinal Metaplasia.

Authors:  Paulius Jonaitis; Limas Kupcinskas; Juozas Kupcinskas
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

3.  Study on the Diagnosis of Gastric Cancer by Magnetic Beads Extraction and Mass Spectrometry.

Authors:  Ning Zhu; Xiaoliang Xing; Limei Cao; Yingjun Zhang; Ti Zhang; Zhen Li; Fen Zou; Qing Li
Journal:  Biomed Res Int       Date:  2020-08-05       Impact factor: 3.411

Review 4.  Chronic atrophic gastritis: an update on diagnosis.

Authors:  Adriana Botezatu; Nicolae Bodrug
Journal:  Med Pharm Rep       Date:  2021-01-29

5.  Mitochondrial DNA Copy Number Variations and Serum Pepsinogen Levels for Risk Assessment in Gastric Cancer

Authors:  Mehdi Alikhani; Samaneh Saberi; Maryam Esmaeili; Valérie Michel; Mohammad Tashakoripour; Afshin Abdirad; Arezoo Aghakhani; Sana Eybpoosh; Massoud Vosough; Mohammad Ali Mohagheghi; Mahmoud Eshagh Hosseini; Eliette Touati; Marjan Mohammadi
Journal:  Iran Biomed J       Date:  2021-08-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.